Comments
Lupin on Monday informed the exchanges that it has received tentative approval for its Lurasidone Hydrochloride tablets from the US Food and Drug Administration to market the generic version of Sunovion Pharmaceuticals’ Latuda tablets.
The medicine is for the treatment of adults with schizophrenia; monotherapy treatment of adults with major depressive episodes associated with bipolar I disorder (bipolar depression); and adjunctive treatment with lithium or valproate in adult patients with major depressive episodes associated with bipolar I disorder.
Lurasidone Hydrochloride tablets had annual sales of approximately $3116 million in the US. Shares of Lupin closed at ₹880.45, up 4.15 per cent.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.